This inventor holds 10 USPTO granted patents and 1 published patent application. Top assignees: University of Kentucky Research Foundation, Other. Active years: 2012-2017.
Location History:
- Richmond, KY (US) (2013)
- Lexington, KY (US) (2012 - 2017)
Company Filing History:
8 out of 903 
2 out of 834,411 Years Active: 2012-2017
Title: Sangeetha Sumithran: Innovator in Neuronal Modulation
Introduction
Sangeetha Sumithran is a prominent inventor based in Lexington, KY (US). She has made significant contributions to the field of neuroscience through her innovative research and development of compounds that interact with neuronal nicotinic acetylcholine receptors. With a total of 10 patents to her name, her work has the potential to impact the treatment of various central nervous system disorders.
Latest Patents
One of her latest patents is focused on bis-quaternary ammonium cyclophane compounds that modulate nicotinic acetylcholine receptors. These compounds are designed to aid in the prevention and treatment of central nervous system disorders, substance use and abuse, and gastrointestinal tract disorders. Another notable patent involves monoquaternary ammonium salts, which also serve as modulators of nicotinic acetylcholine receptors, providing methods for their application in similar therapeutic areas.
Career Highlights
Sangeetha has worked with the University of Kentucky Research Foundation, where she has been able to leverage her expertise in neuroscience to develop groundbreaking solutions. Her research has garnered attention for its potential applications in treating complex health issues.
Collaborations
Throughout her career, Sangeetha has collaborated with esteemed colleagues, including Linda P Dwoskin and Peter Anthony Crooks. These partnerships have enriched her research and contributed to the advancement of her innovative projects.
Conclusion
Sangeetha Sumithran's work exemplifies the intersection of innovation and healthcare, particularly in the realm of neuronal modulation. Her contributions are paving the way for new treatments that could significantly improve the quality of life for individuals with central nervous system disorders.